AstraZeneca
AstraZeneca to Use Tracer Biotechnologies Cancer Monitoring Tech for Clinical Trials
Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
Owkin, AstraZeneca Partner to Develop AI-Based Breast Cancer Prescreening Tool
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
In Brief This Week: Illumina, Sophia Genetics, Thermo Fisher, Oxford Nanopore, Agilent, More
News items for the week of Sept. 9, 2024.